|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2009-11-26
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
In patients with long-standing type 1 diabetes, we investigated whether improved beta-cell function can be achieved by combining intensive insulin therapy with agents that may 1) promote beta-cell growth and/or limit beta-cell apoptosis and 2) weaken the anti-beta-cell autoimmunity.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DRB1 Chains,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Venoms,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab,
http://linkedlifedata.com/resource/pubmed/chemical/exenatide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1935-5548
|
|
pubmed:author |
pubmed-author:BaronAlainA,
pubmed-author:Brooks-WorrellBarbaraB,
pubmed-author:ChenKimK,
pubmed-author:DigonBenigno JBJ3rd,
pubmed-author:DoschH-MichaelHM,
pubmed-author:HarlanDavid MDM,
pubmed-author:NelsonPatricP,
pubmed-author:PalmerJerry PJP,
pubmed-author:RingMichaelM,
pubmed-author:RotherKristina IKI,
pubmed-author:SpainLisa MLM,
pubmed-author:WesleyRobert ARA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2251-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19808924-Adult,
pubmed-meshheading:19808924-Age of Onset,
pubmed-meshheading:19808924-Antibodies, Monoclonal,
pubmed-meshheading:19808924-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19808924-Autoimmunity,
pubmed-meshheading:19808924-Cross-Over Studies,
pubmed-meshheading:19808924-Diabetes Mellitus, Type 1,
pubmed-meshheading:19808924-Drug Therapy, Combination,
pubmed-meshheading:19808924-Female,
pubmed-meshheading:19808924-HLA-DR Antigens,
pubmed-meshheading:19808924-HLA-DRB1 Chains,
pubmed-meshheading:19808924-Hemoglobin A, Glycosylated,
pubmed-meshheading:19808924-Humans,
pubmed-meshheading:19808924-Hypoglycemic Agents,
pubmed-meshheading:19808924-Immunoglobulin G,
pubmed-meshheading:19808924-Immunosuppressive Agents,
pubmed-meshheading:19808924-Insulin,
pubmed-meshheading:19808924-Insulin-Secreting Cells,
pubmed-meshheading:19808924-Male,
pubmed-meshheading:19808924-Peptides,
pubmed-meshheading:19808924-Questionnaires,
pubmed-meshheading:19808924-Research Design,
pubmed-meshheading:19808924-United States,
pubmed-meshheading:19808924-Venoms,
pubmed-meshheading:19808924-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
|
|
pubmed:affiliation |
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. kristina.rother@nih.gov
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, N.I.H., Intramural
|
